Linked Life Data

21557146

Source:http://linkedlifedata.com/resource/pubmed/id/21557146

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2011-5-10
pubmed:abstractText
Epilepsy with myoclonic absences (EMA) is a rare epileptic syndrome with frequently poor response to antiepileptic treatment. Rufinamide (RUF) is a relatively new EMEA- and FDA-approved anticonvulsant licensed as an orphan drug for the adjunctive treatment of patients with Lennox-Gastaut syndrome.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1439-1899
pubmed:author
pubmed:copyrightInfo
© Georg Thieme Verlag KG Stuttgart · New York.
pubmed:issnType
Electronic
pubmed:volume
42
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
28-9
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Epilepsy with myoclonic absences - favourable response to add-on rufinamide treatment in 3 cases.
pubmed:affiliation
Department of Pediatrics, University Hospital, RWTH Aachen, Aachen, Germany. haeusler@rwth-aachen.de
pubmed:publicationType
Journal Article, Case Reports